Washington has invested nine billion US $in vaccines

Washington a investi neuf milliards $US dans les vaccins

Washington a investi neuf milliards $US dans les vaccins

The new billion will fund a demonstration project of large-scale manufacture of its investigational vaccine, with the delivery promised 100 million doses, if the vaccine proves its effectiveness.

Share

5 August 2020 16: 57

Share

Washington has invested nine billion US $in vaccines

Agence France-Presse

WASHINGTON — The government of Donald Trump on Wednesday announced a new investment of one billion US $in the vaccine project, the COVID-19 of the pharmaceutical company Johnson & Johnson, raising the total investment to more than nine billion US$.

Johnson & Johnson, through its subsidiary Janssen, has already received the end of march 456 million US$. The new billion will fund a demonstration project of large-scale manufacture of its investigational vaccine, with the delivery promised 100 million doses, if the vaccine proves its effectiveness. The parties provide for a potential amendment of $ 200 million additional doses.

This cheque brought up the us public investment to at least $ 9.4 billion US $in vaccine projects, including supply contracts signed with five companies providing for the delivery of at least 700 million doses, according to a count by the AFP.

Provided that the vaccines are licensed, the United States could obtain, in theory, 100 million doses of four groups (Johnson & Johnson, Novavax, Pfizer/BioNTech, Sanofi/GSK), and 300 million doses of Oxford/AstraZeneca, the latter alliance has also signed or is in negotiations with other countries, including 400 million doses to the european Union.

The race to vaccines requires that you run the production in parallel of clinical trials and potentially at a loss, before we even know if the vaccine is effective.

The most advanced project in the United States is one of the national Institutes of health (NIH), associated with the biotech Moderna. The last phase of clinical trials has been launched at the end of July, a record time “, which would have been unthinkable a decade ago”, pointed out Wednesday, Anthony Fauci, who heads the institute of infectious diseases, managing the trial, during an exchange organized by Harvard university.

He hopes to recruit 30,000 participants by three months, of which half will receive a placebo. It will then wait to see if the placebo group is naturally more infected with the coronavirus that the vaccinated group.

“My estimate, which is only an estimate, is that towards the end of the year or at the beginning of 2021, we will know if we have a vaccine that is safe and effective. ”


Dr. Anthony Fauci, director of the institute of infectious diseases

“I am cautiously optimistic about our success,” he added, because of the immune response generated by the vaccine in tests on a small number of volunteers since march.

The u.s. government has also spent billions for the construction of production sites, for companies in the manufacturing of syringes and vials that will be required to distribute or future vaccines, not to mention the support given to the development of treatments.

The United States has purchased virtually all of the production of the antiviral drug remdesivir until September, the first to have demonstrated a relative benefit for the sick of the COVID-19.

Le Soleil

Share Button

Add a Comment

Your email address will not be published. Required fields are marked *